BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2549567)

  • 1. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres.
    Houle S; Yip TK; Shepherd FA; Rotstein LE; Sniderman KW; Theis E; Cawthorn RH; Richmond-Cox K
    Radiology; 1989 Sep; 172(3):857-60. PubMed ID: 2549567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of
    Ng CWQ; Bin Hassan MJ; Goh C; Tong AKT; Tham WY; Thang SP; Lam WW; Low HC; Magsombol BM; Loke KSH
    J Nucl Med Technol; 2024 Jun; 52(2):148-151. PubMed ID: 38839117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A microscopic model of the dose distribution in hepatocellular carcinoma after selective internal radiation therapy.
    Cutrì E; Morel-Corlu E; Rolland Y; Saint-Jalmes H; Eliat PA; Garin E; Bezy-Wendling J
    Phys Med; 2024 Jun; 122():103384. PubMed ID: 38824827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Vimalnath KV; Rajeswari A; Dixit A; Chakravarty R; Sarma HD; Kulkarni S; Jha A; Puranik A; Rangarajan V; Goswami M; Chakraborty S
    Cancer Biother Radiopharm; 2024 Feb; 39(1):82-91. PubMed ID: 38265675
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up.
    Andrews JC; Walker SC; Ackermann RJ; Cotton LA; Ensminger WD; Shapiro B
    J Nucl Med; 1994 Oct; 35(10):1637-44. PubMed ID: 7931662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure.
    Pasciak AS; Abiola G; Liddell RP; Crookston N; Besharati S; Donahue D; Thompson RE; Frey E; Anders RA; Dreher MR; Weiss CR
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):816-827. PubMed ID: 31741021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective internal radiation therapy segmentectomy: A new minimally invasive curative option for primary liver malignancies?
    Inchingolo R; Cortese F; Pisani AR; Acquafredda F; Calbi R; Memeo R; Anagnostopoulos F; Spiliopoulos S
    World J Gastroenterol; 2024 May; 30(18):2379-2386. PubMed ID: 38764771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma.
    Lee HM; Alder L; Nguyen M; Dougherty SC; Qu Y; Thacker LR; Poklepovic A
    J Gastrointest Oncol; 2023 Jun; 14(3):1378-1391. PubMed ID: 37435218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy.
    Feng R; Cheng DX; Song T; Chen L; Lu KP
    World J Gastrointest Surg; 2023 Apr; 15(4):687-697. PubMed ID: 37206075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges.
    Salih S; Alkatheeri A; Alomaim W; Elliyanti A
    Molecules; 2022 Aug; 27(16):. PubMed ID: 36014472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioembolization for the Treatment of Hepatocellular Carcinoma: The Road to Personalized Dosimetry and Ablative Practice.
    De la Garza-Ramos C; Toskich BB
    Semin Intervent Radiol; 2021 Oct; 38(4):466-471. PubMed ID: 34629715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Therapies for the Treatment of Hepatocellular Carcinoma.
    Parikh ND; Cuneo K; Mendiratta-Lala M
    Clin Liver Dis (Hoboken); 2021 May; 17(5):341-346. PubMed ID: 34136139
    [No Abstract]   [Full Text] [Related]  

  • 14. Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy.
    Roncali E; Capala J; Benedict SH; Akabani G; Bednarz B; Bhadrasain V; Bolch WE; Buchsbaum JC; Coleman NC; Dewaraja YK; Frey E; Ghaly M; Grudzinski J; Hobbs RF; Howell RW; Humm JL; Kunos CA; Larson S; Lin FI; Madsen M; Mirzadeh S; Morse D; Pryma D; Sgouros G; St James S; Wahl RL; Xiao Y; Zanzonico P; Zukotynski K
    J Nucl Med; 2021 Aug; 62(8):1133-1139. PubMed ID: 33277396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy.
    Karimian A; Ji NT; Song H; Sgouros G
    Cancer Res; 2020 Feb; 80(4):868-876. PubMed ID: 31772036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(3-hydroxi-butyrate-co-3-hydroxy-valerate) (PHB-HV) microparticles loaded with holmium acetylacetonate as potential contrast agents for magnetic resonance images.
    de Azevedo MBM; Melo VH; Soares CR; Gamarra LF; Barros CH; Tasic L
    Int J Nanomedicine; 2019; 14():6869-6889. PubMed ID: 31507318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma.
    Saini A; Wallace A; Alzubaidi S; Knuttinen MG; Naidu S; Sheth R; Albadawi H; Oklu R
    J Clin Med; 2019 Jan; 8(1):. PubMed ID: 30621040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phantom validation of quantitative Y-90 PET/CT-based dosimetry in liver radioembolization.
    D'Arienzo M; Pimpinella M; Capogni M; De Coste V; Filippi L; Spezi E; Patterson N; Mariotti F; Ferrari P; Chiaramida P; Tapner M; Fischer A; Paulus T; Pani R; Iaccarino G; D'Andrea M; Strigari L; Bagni O
    EJNMMI Res; 2017 Nov; 7(1):94. PubMed ID: 29185067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Kis B; El-Haddad G; Sheth RA; Parikh NS; Ganguli S; Shyn PB; Choi J; Brown KT
    Cancer Control; 2017; 24(3):1073274817729244. PubMed ID: 28975829
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.